Investment Thesis
Amylyx Pharmaceuticals faces severe financial distress with zero revenue, mounting operating losses of $153.3M, and negative free cash flow of $123.5M, indicating the company is burning cash at an unsustainable rate. Despite a strong cash position of $226.7M, the company's lack of commercial revenue generation combined with deteriorating fundamentals suggests existential challenges to long-term viability.
AMLX Strengths
- Substantial cash reserves of $226.7M provides runway for operations
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial risk
- Strong liquidity position with 14.27x current ratio ensures short-term solvency
AMLX Risks
- Complete revenue collapse with $0.00 in reported revenue indicates failed commercialization or major business setback
- Continuous operating losses of $153.3M with negative free cash flow of $123.5M unsustainable even with current cash reserves
- Negative ROE of -47.4% and ROA of -43.5% demonstrate value destruction and inefficient capital allocation
- High insider trading activity (22 Form 4 filings in 90 days) may signal insiders managing positions during distress
Key Metrics to Watch
- Cash burn rate and remaining runway before capital exhaustion
- Revenue generation from approved products and clinical pipeline progress
- Operating expense reduction initiatives and path to profitability
AMLX Financial Metrics
AMLX Profitability Ratios
AMLX Balance Sheet & Liquidity
AMLX 5-Year Financial Trend
5-Year Trend Summary: Amylyx Pharmaceuticals, Inc.'s revenue has grown significantly by 293% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.43 indicates the company is currently unprofitable.
AMLX Growth Metrics (YoY)
AMLX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$34.4M | $-0.37 |
| Q2 2025 | -$1.0M | -$35.9M | $-0.46 |
| Q1 2025 | N/A | -$35.9M | $-0.42 |
| Q3 2024 | $416.0K | $1.6M | $0.30 |
| Q2 2024 | -$1.0M | $1.6M | $0.31 |
| Q1 2024 | $71.4M | $1.6M | $0.02 |
| Q3 2023 | $345.0K | $1.6M | $0.30 |
| Q2 2023 | $98.2M | $1.6M | $0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AMLX Capital Allocation
AMLX SEC Filings
Access official SEC EDGAR filings for Amylyx Pharmaceuticals, Inc. (CIK: 0001658551)